Physician profile
Anna Milstein
NPI 1003914227
$42,330.47
in general payments reported to CMS, 2019-2025
66 companies · $3,205 in 2025
The $3,205 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,132 · 2021: $6,391 · 2022: $8,634 · 2023: $3,658 · 2024: $3,383 · 2025: $3,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,181.55 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20,905.79 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,986.90 | 2019-2025 | |
| Amgen INC. | $1,928.53 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $1,520.25 | 2019-2025 | Farxiga, Breztri, Brilinta |
| Amarin Pharma, INC. | $1,446.86 | 2019-2023 | |
| Abbvie INC. | $1,372.46 | 2019-2025 | |
| Lilly USA, LLC | $904.15 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $877.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $768.81 | 2019-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $767.53 | 2019-2023 | |
| Pfizer INC. | $733.02 | 2019-2025 | |
| Novo Nordisk INC | $714.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $649.44 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Edwards Lifesciences Corporation | $609.28 | 2019-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $545.67 | 2019-2025 | Camzyos, Eliquis |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.00 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $469.72 | 2019-2024 | Trintellix |
| Arbor Pharmaceuticals, INC. | $400.00 | 2019-2022 | |
| Esperion Therapeutics, INC. | $387.78 | 2021-2025 | Nexletol |
| Radius Health, INC. | $365.34 | 2021-2025 | Tymlos |
| Ibsa Pharma INC. | $352.86 | 2020-2025 | Tirosint, Licart, Tirosint |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.60 | 2019-2025 | Lifevest |
| Vifor Pharma, INC. | $255.29 | 2019-2024 | Veltassa |
| Shield Therapeutics INC | $231.39 | 2022-2025 | Accrufer |
| Lexicon Pharmaceuticals, INC. | $231.26 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $185.61 | 2023-2025 | Amvuttra, Onpattro |
| Mallinckrodt Hospital Products INC. | $181.62 | 2023-2025 | Acthar |
| Paratek Pharmaceuticals, INC. | $180.49 | 2022-2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $172.01 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $170.12 | 2020-2023 | |
| Ironwood Pharmaceuticals, INC | $164.11 | 2020-2023 | Linzess |
| Vivus LLC | $148.44 | 2022-2025 | Pancreaze |
| Horizon Therapeutics Plc | $138.36 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $128.81 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $117.87 | 2019 | |
| Aimmune Therapeutics, INC. | $106.80 | 2024-2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company Ltd. | $105.16 | 2022 | |
| Boston Scientific Corporation | $104.57 | 2019-2024 | Bodyguardian, Watchman Flx |
| Eisai INC. | $102.35 | 2020-2022 | |
| Fidia Pharma USA INC. | $94.72 | 2019-2020 | |
| Scpharmaceuticals INC. | $88.73 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.56 | 2019-2023 | Xifaxan |
| Tactile Systems Technology INC | $74.31 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Actelion Pharmaceuticals US, INC. | $71.83 | 2021-2022 | |
| Irhythm Technologies, INC. | $65.83 | 2024 | Zio Xt Patch, Zio Monitor |
| Ucb, INC. | $65.73 | 2024 | Cimzia, Bimzelx |
| Idorsia Pharmaceuticals US INC | $59.81 | 2023 | Quviviq |
| Medtronic, INC. | $54.94 | 2022-2023 | Azure Xt Dr Mri Surescan |
| Daiichi Sankyo INC. | $48.12 | 2019 | |
| Heartflow, INC. | $46.83 | 2023 | Ffrct |
| Allergan, INC. | $39.76 | 2019-2020 | |
| Baxter Healthcare | $38.94 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Exact Sciences Corporation | $33.88 | 2023-2024 | Cologuard Collection Kit |
| Zimmer Biomet Holdings, INC. | $31.11 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Janssen Scientific Affairs, LLC | $28.99 | 2021 | |
| Cvrx, INC. | $26.00 | 2024 | Barostim Neo System |
| Janssen Biotech, INC. | $24.80 | 2019 | |
| Mylan Specialty L.P. | $22.68 | 2019 | |
| Abbott Laboratories | $21.88 | 2020 | |
| Depuy Synthes Sales INC. | $21.62 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.48 | 2021 | |
| Avanos Medical | $16.24 | 2023 | Trivisc Sodium Hyaluronate |
| Sun Pharmaceutical Industries INC. | $15.16 | 2021 | |
| Cmp Pharma, INC. | $14.31 | 2019 | |
| Medicure Pharma INC. | $14.02 | 2023 | Zypitamag |
| Gilead Sciences, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Milstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.